Tracking Early Decline in Cognitive Function in Older Individuals at Risk for Alzheimer Disease Dementia The Alzheimer's Disease Cooperative Study Cognitive Function Instrument

摘要: Importance Several large-scale Alzheimer disease (AD) secondary prevention trials have begun to target individuals at the preclinical stage. The success of these depends on validated outcome measures that are sensitive early clinical progression in who initially asymptomatic. Objective To investigate utility Cognitive Function Instrument (CFI) track changes cognitive function older without impairment baseline. Design, Setting, and Participants Longitudinal study from February 2002 through 2007 participating Alzheimer’s Disease Cooperative Study sites. Individuals were followed up annually for 48 months after baseline visit. included 468 healthy (Clinical Dementia Rating scale [CDR] global scores 0, above cutoff modified Mini-Mental State Examination Free Cued Selective Reminding Test) (mean [SD] age, 79.4 [3.6] years; age range, 75.0-93.8 years). All participants their partners completed self partner CFIs annually. also underwent concurrent annual neuropsychological assessment APOE genotyping. Main Outcomes Measures CFI scores between progressors (CDR score, ≥0.5) nonprogressors 0) e4 carriers noncarriers compared. Correlations change performance assessed longitudinally. Results At months, group differences non-progressors significant (2.13, SE=0.45, P had greater than (1.10, SE=0.44, Conclusions Relevance Demonstrating long-term benefit will be critical recently launched trials. appears a brief, but informative potential measure provides insight into functional abilities earliest stages disease.